ArticleFrontiers in immunology2022

Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig

Roger H Kobayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.